Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
FHTX Stock Chart & Stats
$5.09
$0.09(1.92%)
At close: 4:00 PM EST
$5.09
$0.09(1.92%)
Day’s Range― - ―
52-Week Range$2.94 - $6.95
Previous CloseN/A
Volume24.60K
Average Volume (3M)157.41K
Market Cap
$298.78M
Enterprise Value$259.18M
Total Cash (Recent Filing)$158.89M
Total Debt (Recent Filing)$41.27M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 11, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding58,700,245
10 Day Avg. Volume207,613
30 Day Avg. Volume157,412
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-3.13
Price to Sales (P/S)11.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue8.39
Enterprise Value/Gross Profit28.16
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$11.67Price Target Upside129.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1
Revenue Forecast (FY)$42.12M
Bulls Say, Bears Say
Bulls Say
Combination Strategy PotentialAnalyst highlights preclinical evidence that the lead candidate and other programs increase anti-tumor activity when combined with chemotherapy, PD‑1 inhibitors, or KRAS inhibitors, supporting potential combination strategies in lung cancer.
Pipeline Expansion From Selective DegradersAnalyst points to advancement of selective CBP, EP300, and ARID1B programs toward investigational studies, which could broaden the company's clinical-stage portfolio and add value beyond the partnered asset.
Strategic Pharmaceutical PartnershipAnalyst notes that the collaboration with a major pharmaceutical partner on a first‑in‑class SMARCA2 inhibitor could accelerate development decisions and lend credibility to trial outcomes if the partner advances dosing.
Bears Say
Binary Clinical Outcome RiskAnalyst warns that clinical success depends on dose‑escalation results for the lead program, creating a binary outcome risk that could materially affect valuation if results are unfavorable.
Funding And Dilution RiskAnalyst cautions that restarting development of a previously discontinued asset could require additional funding and raise the risk of shareholder dilution amid multiple ongoing clinical programs.
Revenue ShortfallAnalyst points out that collaboration revenue fell short of expectations, representing a negative near-term financial signal that could pressure the stock.
Foghorn Therapeutics News
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $2.94 and its highest was $6.95 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $298.78M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is May 11, 2026 which is in 47 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Mar 11, 2026. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.264 by -$0.086.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.31.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 58,700,245 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.264. Following the earnings report the stock price went down -12.92%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Foghorn Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.67 (129.27% Upside)
$11.67 (129.27% Upside)
Hedge Fund Trend
Increased
By 306.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.2%
Last 30 Days ▲ 9.4%
Last 30 Days ▲ 9.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.32%
12-Months-Change
Fundamentals
Return on Equity
105.48%
Trailing 12-Months
Asset Growth
-33.53%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FHTX Stock 12 Month Forecast
Average Price Target
$11.67
▲(129.27% Upside)
Technical Analysis
Ownership Overview
1.10% Insiders
9.16% Mutual Funds
42.81% Other Institutional Investors
41.60% Public Companies and
Individual Investors